This study, called SOLAIRIA-2, is looking at whether GB-0895 can help adults and adolescents (ages 12 to 80) with severe asthma that isn't well-controlled by their current medications. You must have had asthma for at least two years and be on specific asthma controllers for a certain time. Participants will receive either GB-0895 or a placebo (an inactive substance) every six months for 52 weeks. The main goal is to see if GB-0895 can reduce the number of asthma attacks (exacerbations) over this period. The study aims to enroll about 786 people globally, but its current status is unclear.

Study design

This is a global, randomized, double-blind, placebo-controlled Phase 3 study involving approximately 786 participants.

What's involved

You would have visits every 1-2 months after the first month, for a total treatment period of 52 weeks.

Compensation

Not stated in the trial record.

Follow-up

You would be followed for up to 90 weeks, or potentially up to 142 weeks if you join an optional open-label extension.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.